title: Response to Tomsak, R. PDE5 inhibitors and permanent visual loss (Int J Impot Res 2005; 17: 547-549).
authors.forename: S J
authors.initials: SJ
authors.lastname: Watt
authors.forename: P
authors.initials: P
authors.lastname: Primatesta
authors.forename: R
authors.initials: R
authors.lastname: Siegel
mesh_terms: D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D008297:Male; D009900:Optic Nerve / Q000033:anatomy & histology / Q000187:drug effects; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced*; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects*; D010879:Piperazines / Q000009:adverse effects; D011687:Purines; D012307:Risk Factors; D000068677:Sildenafil Citrate; D013450:Sulfones
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate